The Fee Increase Is a Tax on American Patients
The Food and Drug Administration has published its proposed user fees for fiscal year 2027, and the numbers should alarm anyone who depends on medical innovation. The standard 510(k) premarket notification fee would rise to roughly $25,000, while the small business rate would climb above $12,000. For a startup operating on a seed round, that is not a rounding error. It is a barrier. The FDA collects these fees to fund its review process, but the agency has turned the program into a regressive tax. Large companies pay the same per-application rate as firms with a handful of employees. That is not how you encourage competition.
The agency says it needs more resources to speed reviews. Americans have heard that before. The standard 510(k) review now averages about 180 days, and some submissions sit for more than ten months. A fee hike might be defensible if it came with a binding service-level agreement. It does not. Companies hand over tens of thousands of dollars and then wait half a year for an answer. The FDA gets the money whether it meets a deadline or not. That is a monopoly pricing power that no private regulator could sustain.
Small Firms Bear the Heaviest Load
The medical device industry supports roughly two million American jobs, and the vast majority of companies employ fewer than fifty people. These firms produce the catheters, surgical tools, diagnostic sensors, and implantable devices that make modern medicine possible. They also operate on thin margins and long development timelines. A $25,000 submission fee might be a line item for Medtronic or Boston Scientific. For a company in Austin or Raleigh with eight employees, it can be the difference between filing and folding.
The small business discount helps, but the qualification rules are narrow. A company must have annual sales of $100 million or less to claim the reduced rate. That sounds generous until you realize how quickly medical device revenue can exceed the cap after a first product launch. The discount also does not apply to most consulting and testing costs that surround a submission. By the time a firm has finished biocompatibility studies, electrical safety testing, and clinical data collection, it may have spent several hundred thousand dollars. The FDA fee is just one more weight on the scale.
Europe used to be the easy comparison point. The Medical Device Regulation that took full effect in recent years made European approvals slower and more expensive. American regulators used to boast that the United States was the faster market. That advantage is fading. If Congress allows the FDA to keep raising fees without demanding accountability, more startups will file in Singapore, Australia, or the European Union first. Patients in the United States will wait longer for the same devices.
Accountability, Not Just Money
User fees are not inherently bad. They can align the incentives of regulators and applicants. The current system aligns only one incentive: the FDA's desire for a bigger budget. Congress should tie every fee increase to measurable review-time improvements. If the agency cannot process a standard 510(k) within 90 days, it should not collect a full fee. That is how a service provider would operate. Government agencies should face the same discipline.
Lawmakers should also expand the small business discount and index it to inflation more carefully. A $100 million revenue cap made sense years ago. Medical economics have changed. Startups that reach $120 million in sales are still small compared with the giants that dominate hospital supply chains. Punishing them with the full fee is shortsighted. The goal should be to get new technology into clinics, not to maximize fee revenue.
Finally, Congress should require the FDA to publish clear guidance on when a 510(k) needs clinical data and when it does not. Uncertainty drives up legal bills and delays submissions. Companies hire consultants to guess what reviewers want. A transparent rulebook would reduce costs across the board and let engineers focus on engineering rather than regulatory astrology.
The Cost of Getting It Wrong
The medical device industry does not need deregulation. It needs predictable, proportional regulation. A $25,000 filing fee from an agency that averages six-month delays is neither. It is a tax on hope. It tells the entrepreneur in Minneapolis or the engineer in Salt Lake City that their breakthrough must wait until they can afford a regulator's toll.
Patients pay the price when devices reach market later. A diagnostic tool that catches cancer earlier, a valve that reduces open-heart surgery, or a wearable that warns of stroke risk cannot help anyone while it sits in a federal queue. Every month of delay is measured in lives, not just dollars. That is why fee hikes are not merely an accounting issue. They are a moral issue.
Congress will soon decide whether to renew and expand the FDA's user fee authority. It should do so only if the agreement includes hard deadlines, transparent guidance, and meaningful relief for small businesses. The agency has asked for more money. Americans should ask for more accountability in return. Innovation is already expensive. Washington should stop making it more expensive on purpose.
